These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38565056)

  • 1. The ion channel basis of pharmacological effects of amiodarone on myocardial electrophysiological properties, a comprehensive review.
    Gelman I; Sharma N; Mckeeman O; Lee P; Campagna N; Tomei N; Baranchuk A; Zhang S; El-Diasty M
    Biomed Pharmacother; 2024 May; 174():116513. PubMed ID: 38565056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
    Riera AR; Uchida AH; Ferreira C; Ferreira Filho C; Schapachnik E; Dubner S; Zhang L; Moffa PJ
    Cardiol J; 2008; 15(3):209-19. PubMed ID: 18651412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.
    Witchel HJ; Hancox JC
    Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):753-66. PubMed ID: 11022966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac hERG K
    Su S; Sun J; Wang Y; Xu Y
    Handb Exp Pharmacol; 2021; 267():139-166. PubMed ID: 33829343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
    Singh BN; Wadhani N
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
    Thomas D; Karle CA; Kiehn J
    Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome.
    van Opstal JM; Schoenmakers M; Verduyn SC; de Groot SH; Leunissen JD; van Der Hulst FF; Molenschot MM; Wellens HJ; Vos MA
    Circulation; 2001 Nov; 104(22):2722-7. PubMed ID: 11723026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents.
    Lin C; Ke X; Cvetanovic I; Ranade V; Somberg J
    Cardiology; 2007; 108(1):18-27. PubMed ID: 16960444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA; Kluger J; White CM
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current classification of anti-arrhythmia agents].
    Weirich J; Wenzel W
    Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theoretical possibilities for the development of novel antiarrhythmic drugs.
    Varró A; Biliczki P; Iost N; Virág L; Hála O; Kovács P; Mátyus P; Papp JG
    Curr Med Chem; 2004 Jan; 11(1):1-11. PubMed ID: 14754422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular and ionic specificity of antiarrhythmic drug actions.
    Nattel S
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):272-82. PubMed ID: 10090234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart.
    Sicouri S; Moro S; Litovsky S; Elizari MV; Antzelevitch C
    J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1269-79. PubMed ID: 9395170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of HERG potassium channel function by drug action.
    Thomas D; Karle CA; Kiehn J
    Ann Med; 2004; 36 Suppl 1():41-6. PubMed ID: 15176423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sotalol: An important new antiarrhythmic.
    Anderson JL; Prystowsky EN
    Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms underlying the QT interval-prolonging effects of sevoflurane and its interactions with other QT-prolonging drugs.
    Kang J; Reynolds WP; Chen XL; Ji J; Wang H; Rampe DE
    Anesthesiology; 2006 May; 104(5):1015-22. PubMed ID: 16645454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone.
    Gierten J; Ficker E; Bloehs R; Schweizer PA; Zitron E; Scholz E; Karle C; Katus HA; Thomas D
    Naunyn Schmiedebergs Arch Pharmacol; 2010 Mar; 381(3):261-70. PubMed ID: 19777211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol.
    Merot J; Charpentier F; Poirier JM; Coutris G; Weissenburger J
    Cardiovasc Res; 1999 Nov; 44(2):303-14. PubMed ID: 10690307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels.
    Kiehn J; Thomas D; Karle CA; Schöls W; Kübler W
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Mar; 359(3):212-9. PubMed ID: 10208308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.